نتایج جستجو برای: recombinant human erythropoietin
تعداد نتایج: 1714884 فیلتر نتایج به سال:
we have used recombinant human erythropoietin (r-huepo) in children with chronic renal failure. there was significant improvement in anemia and wellbeing, along with regression of left ventricular mass and no change in the rate of decline of renal function. it is safe and effective in the pre-dialysis as well as the hemodialysis period. considering the benefits of r-huepo, transplantation in ch...
Background: In patients undergoing chemotherapy for cancer, anemia is part of the progression of the disease. Considering the effects of anemia on quality of life of the patients, the prevention and treatment of chemotherapy-induced anemia is crucial. This study was aimed to evaluate the efficacy of recombinant human erythropoietin in reducing the need for blood transfusion in children with sol...
Recombinant human erythropoietin therapy was given to 15 patients undergoing long-term hemodialysis with normal cardiac function. None of the patients had hypertension before the erythropoietin therapy and had received no antihypertensive agents. Before and after the erythropoietin therapy M-mode and pulsed Doppler echocardiographic studies, measurements of plasma volume by radioiodinated human...
BACKGROUND Our original demonstration of immunomodulatory effects of erythropoietin in multiple myeloma led us to the search for the cells in the immune system that are direct targets for erythropoietin. The finding that lymphocytes do not express erythropoietin receptors led to the hypothesis that other cells act as direct targets and thus mediate the effects of erythropoietin. The finding tha...
Erythropoietin is a glycohormone involved in the regulation of the blood cell levels. It is a 166 amino acid protein having 3 N-glycosylation and one O-linked glycosylation sites, and is used to treat anaemia related illness. Though human recombinant erythropoietin (rEPO) is produced in CHO cells, the loss in quality control is 80% due to incomplete glycosylation of the rEPO with low levels of ...
Epoetin (recombinant human erythropoietin, EPO) is of proven benefit in the treatment of renal anaemia, and preliminary reports suggest that it may have a role in the management of other anaemic conditions. Pharmacokinetic and therapeutic studies have examined the use of epoetin administered intravenously, intraperitoneally and subcutaneously, and there is accumulating evidence that the last ro...
The clinical development of recombinant human erythropoietin (rHuEPO) has had a remarkable impact on the clinical practice of oncology. A decade ago, randomized, placebo-controlled trials in anemic cancer patients demonstrated that rHuEPO resulted in an improvement in hemoglobin and hematocrit, a reduction in transfusion requirements, and improvement in quality-of-life (QOL) end points. Based o...
sis, as they secrete about 90% of all systemic EPO. The liver makes about 10% of all EPO1,2. Due to its inherent ability to stimulate red cell production, and thus increase oxygen delivery to the tissues, the use of EPO was banned in sports by the International Olympic Committee (IOC) in 19873. Depending on the sports modality, EPO administration to elite athletes may lead to an artificial perf...
High doses of recombinant human erythropoietin (rhEpo) are required for the treatment of chronic anemia. Thus, it is clear that therapy for chronic anemia would greatly benefit from an erythropoietin derivative with increased erythropoietic activity rather than the native endogenous hormone. In this report, the activity of a human Epo-Epo dimer protein, obtained by recombinant technology, is de...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید